Shanghai Labway Clinical Laboratory Co Ltd (301060) - Net Assets
Based on the latest financial reports, Shanghai Labway Clinical Laboratory Co Ltd (301060) has net assets worth CN¥1.68 Billion CNY (≈ $246.14 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.35 Billion ≈ $343.64 Million USD) and total liabilities (CN¥666.33 Million ≈ $97.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Shanghai Labway Clinical Laboratory Co L's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.68 Billion |
| % of Total Assets | 71.63% |
| Annual Growth Rate | 23.49% |
| 5-Year Change | 0.31% |
| 10-Year Change | 167.58% |
| Growth Volatility | 35.95 |
Shanghai Labway Clinical Laboratory Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Shanghai Labway Clinical Laboratory Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Shanghai Labway Clinical Laboratory Co L worth.
Annual Net Assets for Shanghai Labway Clinical Laboratory Co Ltd (2013–2025)
The table below shows the annual net assets of Shanghai Labway Clinical Laboratory Co Ltd from 2013 to 2025. Also explore 301060 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.64 Billion ≈ $240.69 Million |
-9.64% |
| 2024-12-31 | CN¥1.82 Billion ≈ $266.37 Million |
-8.07% |
| 2023-12-31 | CN¥1.98 Billion ≈ $289.76 Million |
-12.87% |
| 2022-12-31 | CN¥2.27 Billion ≈ $332.58 Million |
+38.60% |
| 2021-12-31 | CN¥1.64 Billion ≈ $239.96 Million |
+31.46% |
| 2020-12-31 | CN¥1.25 Billion ≈ $182.53 Million |
+2.82% |
| 2019-12-31 | CN¥1.21 Billion ≈ $177.52 Million |
+2.71% |
| 2018-12-31 | CN¥1.18 Billion ≈ $172.83 Million |
+6.94% |
| 2017-12-31 | CN¥1.10 Billion ≈ $161.60 Million |
+79.66% |
| 2016-12-31 | CN¥614.70 Million ≈ $89.95 Million |
+101.38% |
| 2015-12-31 | CN¥305.25 Million ≈ $44.67 Million |
+51.76% |
| 2014-12-31 | CN¥201.13 Million ≈ $29.43 Million |
+53.78% |
| 2013-12-31 | CN¥130.79 Million ≈ $19.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Labway Clinical Laboratory Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 543.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥530.33 Million | 34.25% |
| Other Components | CN¥1.02 Billion | 65.75% |
| Total Equity | CN¥1.55 Billion | 100.00% |
Shanghai Labway Clinical Laboratory Co Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Labway Clinical Laboratory Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Patrizia AG
XETRA:PAT
|
$644.20 Million |
|
H&R Century Union Corp
SHE:000892
|
$644.53 Million |
|
Xinjiang Yilite Industry Co Ltd
SHG:600197
|
$644.63 Million |
|
mobilezone ag
SW:MOZN
|
$644.79 Million |
|
Carlton Investments Ltd
AU:CIN
|
$643.96 Million |
|
Chipsea Technologies Shenzhen Corp Ltd
SHG:688595
|
$643.74 Million |
|
SK Discovery Co Ltd
KO:006120
|
$643.73 Million |
|
Anpec Electronics
TWO:6138
|
$643.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Labway Clinical Laboratory Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,658,128,422 to 1,548,475,039, a change of -109,653,383 (-6.6%).
- Net loss of 30,746,454 reduced equity.
- Dividend payments of 92,697,831 reduced retained earnings.
- Other comprehensive income increased equity by 653,308.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-30.75 Million | -1.99% |
| Dividends Paid | CN¥92.70 Million | -5.99% |
| Other Comprehensive Income | CN¥653.31K | +0.04% |
| Other Changes | CN¥13.14 Million | +0.85% |
| Total Change | CN¥- | -6.61% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Labway Clinical Laboratory Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 33.65x to 2.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.33 | CN¥10.99 | x |
| 2014-12-31 | CN¥0.50 | CN¥10.99 | x |
| 2015-12-31 | CN¥3.38 | CN¥10.99 | x |
| 2016-12-31 | CN¥6.11 | CN¥10.99 | x |
| 2017-12-31 | CN¥3.06 | CN¥10.99 | x |
| 2018-12-31 | CN¥3.27 | CN¥10.99 | x |
| 2019-12-31 | CN¥3.35 | CN¥10.99 | x |
| 2020-12-31 | CN¥3.47 | CN¥10.99 | x |
| 2021-12-31 | CN¥4.44 | CN¥10.99 | x |
| 2022-12-31 | CN¥5.15 | CN¥10.99 | x |
| 2023-12-31 | CN¥4.40 | CN¥10.99 | x |
| 2024-12-31 | CN¥4.09 | CN¥10.99 | x |
| 2025-12-31 | CN¥3.87 | CN¥10.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Labway Clinical Laboratory Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.12%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.48x
- Recent ROE (-1.99%) is below the historical average (14.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 64.49% | 18.23% | 1.40x | 2.52x | CN¥71.26 Million |
| 2014 | 34.97% | 13.00% | 1.17x | 2.30x | CN¥50.23 Million |
| 2015 | 27.21% | 13.53% | 1.08x | 1.87x | CN¥52.06 Million |
| 2016 | 10.16% | 7.30% | 0.85x | 1.63x | CN¥898.29K |
| 2017 | 0.60% | 0.70% | 0.69x | 1.23x | CN¥-101.44 Million |
| 2018 | 6.37% | 6.97% | 0.73x | 1.25x | CN¥-41.81 Million |
| 2019 | 7.81% | 8.00% | 0.82x | 1.18x | CN¥-25.83 Million |
| 2020 | 9.03% | 8.91% | 0.84x | 1.20x | CN¥-11.85 Million |
| 2021 | 13.03% | 11.46% | 0.84x | 1.35x | CN¥47.35 Million |
| 2022 | 29.92% | 14.70% | 1.12x | 1.82x | CN¥411.00 Million |
| 2023 | -7.95% | -8.46% | 0.56x | 1.68x | CN¥-319.62 Million |
| 2024 | -6.60% | -6.28% | 0.66x | 1.58x | CN¥-275.25 Million |
| 2025 | -1.99% | -2.12% | 0.63x | 1.48x | CN¥-185.59 Million |
Industry Comparison
This section compares Shanghai Labway Clinical Laboratory Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $5,320,445,918
- Average return on equity (ROE) among peers: 20.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | CN¥1.68 Billion | 64.49% | 0.40x | $644.10 Million |
| Berry Genomics Co Ltd (000710) | $41.15 Million | 36.01% | 2.32x | $468.17 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.74 Billion |
| Hangzhou Tigermed Consulting (300347) | $24.06 Billion | 1.68% | 0.19x | $6.20 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $2.91 Billion | 13.92% | 0.48x | $978.07 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $533.70 Million |
| Maccura Biotechnology Co Ltd (300463) | $442.98 Million | 35.71% | 0.42x | $803.41 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $413.71 Million | 15.76% | 0.19x | $558.16 Million |
| BGI Genomics Co Ltd (300676) | $9.44 Billion | 15.48% | 0.51x | $2.43 Billion |
| Amoy Diagnostics Co Ltd (300685) | $756.74 Million | 16.75% | 0.08x | $1.04 Billion |
About Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing… Read more